Evidence map›Paper›PMID 40969936›Full record

ArticleFrontiers in pharmacology2025

Quantitative evaluation of dual-channel drug supply policy on nationally negotiated anti-tumor drugs in Xuzhou: based on interrupted time series analysis.

Zhaohui Qin, Shuo Xu, Qi Li, Xueling Guan, Meng He, Min Zhou, Yan Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhaohui Qin *The Second Clinical Medical School, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Shuo Xu *School of Management, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Qi LiSchool of Management, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xueling GuanSchool of Management, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Meng HeSchool of Management, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Min ZhouSchool of Economics and Management, China University of Mining and Technology, Xuzhou, Jiangsu, China.
Yan XuThe Second Clinical Medical School, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In September 2021, the "dual-channel" supply policy for anti-tumor drugs had launched in China. This policy solved the problem of difficult and expensive access to anti-tumor drugs. This study aims to measure the impacts of the dual-channel policy on indicators of availability, cost, and reimbursement ratio. Methods: This study adopt the interrupted time series analysis method and selects data on anti-tumor drug payments from October 2020 to October 2022 in Xuzhou City for analysis. Results: After September 2021, the cost of anti-tumor drugs has increased significantly, and the number of purchases and reimbursement ratio and other indicators have increased. It is worth noting that the changes in urban and rural residents' health insurance are more significant than those of employees' health insurance. Discussion: The "dual-channel" supply policy has greatly improved accessibility to anti-tumor drugs. It also reduced the financial burden of disease for ordinary residents. Therefore, we need to enhance the sufficiency of policy implementation.

Indexed as

anti-tumor drugsdual-channelinterrupted time-series analysisnationally negotiated drugsquantitative evaluation

Identifiers

PMID40969936
PMCPMC12440743

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.